Dual therapy strategies for COPD: The scientific rationale for LAMA + LABA

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 785-797

  Cohen, Joshua S ^a   Miles, Matthew C ^b   Donohue, James F ^c   Ohar, Jill A ^b  

^a United Lung and Sleep Clinic   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bronchodilator; Chronic bronchitis; COPD treatment; Emphysema; Fixed dose combination

Indexed keywords

ACLIDINIUM BROMIDE; ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; MACROLIDE; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; VILANTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DELAYED RELEASE FORMULATION; DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE COST; HUMAN; INHALER; LUNG FUNCTION; LUNG TRANSPLANTATION; MEDICATION COMPLIANCE; MORTALITY RATE; PATHOGENESIS; QUALITY OF LIFE; REVIEW; SPIROMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; FORECASTING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DRUG COMBINATIONS; FORECASTING; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84964334156     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S54513     Document Type: Review

References (82)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
2. Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):7-16.
3. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435-459.
4. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733-743.
5. Ohar J, Sterling DA, Bleecker E, Donohue J. Changing patterns in asbestos-induced lung disease. Chest. 2004;125(2):744-753.
6. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567-1575.
7. Senior R, Atkinson J. Chronic obstructive pulmonary disease: epidemiology, pathophysiology, and pathogenesis. In: Alfred Fishman M, editor. Fishman’s Pulmonary Diseases and Disorders. Vol. 1. 4th ed. New York, NY: McGraw Hill Medical; 2008:707-728.
8. O’Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev. 2006;15(100):61-67.
9. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(6):591-597.
10. O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832-840.
11. The Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015. Available from: http://www.goldcopd.org. Accessed March 8,2015.
12. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191.
13. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-1422.
14. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184-1192.
15. Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2):81-89.
16. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931.
17. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.
18. Marchetti N, Criner GJ, Albert RK. Preventing acute exacerbations and hospital admissions in COPD. Chest. 2013;143(5):1444-1454.
19. Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER. Do symptoms predict COPD in smokers? Chest. 2010;137(6):1345-1353.
20. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-750.
21. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728-735.
22. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450-504.
23. Jackson M. “Divine stramonium”: the rise and fall of smoking for asthma. Med Hist. 2010;54(2):171-194.
24. Bray GW. The treatment of asthma. Br Med J. 1935;1(3863):119-121.
25. U.S. Food and Drug Administration. Department of Health and Human Services. Tudorza Pressair (aclidinium bromide inhalation powder) approval letter. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202450Orig1s000ltr.pdf. Accessed November 22, 2014.
26. U.S. Food and Drug Administration. Department of Health and Human Services. Incruse Ellipta (umeclidinium bromide inhalation powder) approval letter. 2014.Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205382Orig1s000ltr.pdf. Accessed November 22, 2014.
27. Miles MC, Donohue JF, Ohar JA. Combination therapy for COPD: emerging evidence from recent clinical trials. J Clin Invest. 2011;1(6):879-890.
28. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
29. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250-255.
30. Leidy NK, Sexton CC, Jones PW, et al. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014;69(5):443-449.
31. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
32. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
33. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-919.
34. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257-267.
35. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest. 1994;105(5):1411-1419.
36. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest. 1997;112(6):1514-1521.
37. van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med. 2010;104(7):995-1004.
38. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970-979.
39. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119-127.
40. Anoro™ [prescribing information]. Durham, NC: GlaxoSmithKline plc; 2013. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-MG.PDF. Accessed May 10, 2015.
41. Mahler DA, Kerwin E, Ayers T, et al. FLIGHT: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with COPD. Am J Respir Crit Care Med. Epub July 15, 2015.
42. Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25(6):465-471.
43. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538-1546.
44. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472-486.
45. Sin DD. Wanted: new treatments for COPD. Lancet Respir Med. 2014;2(6):434-436.
46. Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15(1):78.
47. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 μg therapy in COPD: a randomized, controlled study. Chest. 2014;145(5):981-991.
48. CHMP - Committee for Medicinal Products for Human Use. Initial authorisation of Ultibro Breezhaler (indacaterol/glycopyrronium bromide). 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002679/WC500146589.pdf. Accessed August 12, 2014.
49. Novartis. Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA. 2015. Available from: https://www.novartis.com/news/media-releases/novartis-announces-robust-phase-iii-results-qva149-and-nva237-and-submits. Accessed January 29, 2015.
50. European Medicines Agency. Summary of positive opinion for Onbrez Breezhaler (indacaterol maleate). 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001114/WC500059632.pdf. Accessed August 12, 2014.
51. Indacaterol FDA approval information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed August 12, 2014.
52. Initial authorisation Seebri Breezhaler (glycopyrronium bromide). 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002430/WC500129033.pdf. Accessed August 12, 2014.
53. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107(10):1558-1567.
54. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-1494.
55. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study (Supplementary Material). 2013. Available from: http://www.erj.ersjournals.com/content/suppl/2013/09/03/09031936.00200212.DC1/erj02002-2012_online_supplementary_material.pdf. Accessed August 12, 2014.
56. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199-209.
57. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med.2013;1(1):51-60.
58. Asche CV, Leader S, Plauschinat C, et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2012;7:201-209.
59. Bourbeau J, Sebaldt RJ, Day A, et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J. 2008;15(1):13-19.
60. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221.
61. Korn S, Gebner C, Schurmann W, et al. Once daily QVA149 improves dyspnea, quality of life and reduces the rate of exacerbations compared to tiotropium plus formoterol in COPD patients: the quantify study. Am J Respir Crit Care Med. 2014;189:A5982.
62. Gebner C, Schurmann W, Forster K, et al. Once daily QVA149 demonstrates superior improvements in lung function compared to tiotropium plus formoterol: the quantify study. Am J Respir Crit Care Med. 2014;189:A5983.
63. Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43(6):1599-1609.
64. D’Urzo A, Mergel V, Leselbaum A, Caracta C. Efficacy and safety of fixed-dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest. 2013;144(4_MeetingAbstracts):1025A.
65. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
66. Rennard S, D’Urzo A, Jones P, Mergel V, Leselbaum A, Caracta C. Fixed-dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. Am J Respir Crit Care Med. 2014;189:A6007.
67. Donohue JF, D’Urzo A, Singh D, et al. Cardiovascular safety of fixed-dose combination aclidinium bromide/formoterol fumarate: results of two 6-month studies in patients with moderate to severe COPD. Am J Respir Crit Care Med. 2014;189:A6011.
68. U.S. Food and Drug Administration. Department of Health and Human Services. Stiolto Respimat (tiotropium bromide and olodaterol inhalation spray) approval letter. 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206756Orig1s000ltr.pdf. Accessed July 30, 2015.
69. Derom E, Westerman J, Grönke L, Hamilton A, Li C, Beeh K. P258 the 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease. Thorax. 2014;69(Suppl 2):A190-A191.
70. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969-979.
71. Reisner C, St Rose E, Strom S, et al. Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Eur Respir J. 2011;38(Suppl 55):879.
72. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830-836.
73. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103.
74. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.
75. Bateman E, Rennard S, Jones P, Molins E, Jin M, Leselbaum A. Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: pooled analysis of two studies. Eur Respir J. 2014;44(Suppl 58):285.
76. Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44(5):1156-1165.
77. IMS Health MIDAS. Top 20 global products. 2013. Available from: http://www.imshealth.com/cds/imshealth/Global/Content/Corporate/Press%20Room/Global_2013/Top_20_Global_Products_2013.pdf. Accessed January 1, 2014.
78. Small M, Broomfield S, Higgins V. Quantification and treatment patterns of Real-World Patients Classified by the GOLD 2011 Strategy. Thorax. 2012;67(Suppl 2):A144-A145.
79. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285-1294.
80. Buhl R, Derom E, Ferguson G, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® improves outcomes vs mono-components in COPD in two 1-year studies. Eur Respir J. 2014;44(Suppl 58, OP1895).
81. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831-838.
82. Garcia-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J, Anto JM. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J. 2000;16(6):1037-1042.